Literature DB >> 19539054

Clostridium difficile--a continually evolving and problematic pathogen.

Lisa F Dawson1, Esmeralda Valiente, Brendan W Wren.   

Abstract

Clostridium difficile is a unique pathogen that often predominates in the bowel microflora as a result of the microbial compositional changes following antibiotic treatment. The hospital environment and patients undergoing antibiotic treatment provide a discrete ecosystem where C. difficile persists and where virulent clones thrive. The continued rise of C. difficile infection (CDI) worldwide has been accompanied by the rapid emergence and transcontinental spread of highly virulent clones, designated PCR-ribotypes 017, 027 and 078. These strains have risen from obscurity to become the most frequently isolated C. difficile strain types. Additionally, patients infected with these strains often experience more severe diarrhoea, more recurrent episodes and higher mortality. Although C. difficile appears to be evolving to occupy the hospital niche, community acquired CDI is also on the increase: equally changes in human activity are likely to be responsible for creating the microenvironment for C. difficile to thrive. The rapid worldwide spread of the 017, 027 and 078 clones of C. difficile provides a valuable opportunity to study the very recent emergence of a bacterial pathogen-a rare chance to monitor evolution in action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539054     DOI: 10.1016/j.meegid.2009.06.005

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  19 in total

1.  Mapping interactions between germinants and Clostridium difficile spores.

Authors:  Amber Howerton; Norma Ramirez; Ernesto Abel-Santos
Journal:  J Bacteriol       Date:  2010-10-22       Impact factor: 3.490

2.  Dynamic changes of the luminal and mucosa-associated gut microbiota during and after antibiotic therapy with paromomycin.

Authors:  Femke-Anouska Heinsen; Henrik Knecht; Sven C Neulinger; Ruth A Schmitz; Carolin Knecht; Tanja Kühbacher; Philip C Rosenstiel; Stefan Schreiber; Anette K Friedrichs; Stephan J Ott
Journal:  Gut Microbes       Date:  2015-07-04

3.  Visualization of Genetic Drift Processes Using the Conserved Collagen 1α1 GXY Domain.

Authors:  Anne J Kleinnijenhuis
Journal:  J Mol Evol       Date:  2019-03-13       Impact factor: 2.395

Review 4.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 5.  The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.

Authors:  Neehar Parikh; Colin W Howden
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

6.  SleC is essential for germination of Clostridium difficile spores in nutrient-rich medium supplemented with the bile salt taurocholate.

Authors:  David A Burns; John T Heap; Nigel P Minton
Journal:  J Bacteriol       Date:  2009-11-20       Impact factor: 3.490

7.  Coexistence of multiple multilocus variable-number tandem-repeat analysis subtypes of Clostridium difficile PCR ribotype 027 strains within fecal specimens.

Authors:  Hannah E Tanner; Katherine J Hardy; Peter M Hawkey
Journal:  J Clin Microbiol       Date:  2010-01-13       Impact factor: 5.948

8.  Characterisation of Clostridium difficile biofilm formation, a role for Spo0A.

Authors:  Lisa F Dawson; Esmeralda Valiente; Alexandra Faulds-Pain; Elizabeth H Donahue; Brendan W Wren
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

9.  The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile.

Authors:  Glen P Carter; Gillian R Douce; Revathi Govind; Pauline M Howarth; Kate E Mackin; Janice Spencer; Anthony M Buckley; Ana Antunes; Despina Kotsanas; Grant A Jenkin; Bruno Dupuy; Julian I Rood; Dena Lyras
Journal:  PLoS Pathog       Date:  2011-10-13       Impact factor: 6.823

10.  Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.

Authors:  Xiaoxi B Lin; Levinus A Dieleman; Ali Ketabi; Ilona Bibova; Michael B Sawyer; Hongyu Xue; Catherine J Field; Vickie E Baracos; Michael G Gänzle
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.